{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-119941","form_type":"8-K","ticker":"CLRB","cik":"0001279704","company_name":"Cellectar Biosciences, Inc.","filed_at":"2024-11-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:07.954225+00:00","generated_at":"2026-05-29T22:54:59.993578+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Cellectar Q3 cash $34.3M; raised $19.4M with potential $73.3M; positive WM data supports NDA","bullets":["Cash $34.3M at Sept 30, 2024, up from $9.6M at Dec 31, 2023; raised $19.4M from warrant exercises with potential for additional $73.3M.","Q3 R&D expenses $5.5M (down from $7.0M YoY) due to end of WM pivotal enrollment; G&A $7.8M (up from $2.4M YoY) for commercialization prep.","Positive Phase 2 CLOVER-WaM results for iopofosine I 131 in WM; planning near-term NDA submission for accelerated approval.","Data selected for oral presentation at ASH meeting on Dec 9, 2024.","Entered supply agreements (SpectronRx, Northstar) and collaboration with City of Hope for mycosis fungoides."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-119941","json":"https://secwatch.observer/filing/0001104659-24-119941.json","markdown":"https://secwatch.observer/filing/0001104659-24-119941.md","text":"https://secwatch.observer/filing/0001104659-24-119941.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1279704/000110465924119941/0001104659-24-119941-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1279704/000110465924119941/tm2428692d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T22:54:59.993578+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}